Affinage

SSX2

Protein SSX2 · UniProt Q16385

Length
188 aa
Mass
21.6 kDa
Annotated
2026-04-28
61 papers in source corpus 19 papers cited in narrative 19 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SSX2 is a nuclear chromatin-associated protein that functions as a transcriptional repressor and antagonist of polycomb group (PcG) repressive complexes. Its N-terminal KRAB-homology domain mediates transcriptional repression, while the full-length protein binds double-stranded DNA in a sequence-nonspecific manner, destabilizes PcG body formation (including Bmi1 and EZH2), reduces H3K27me3 levels, and derepresses PcG target genes (PMID:7539744, PMID:25249625). SSX2 interacts with SSX2IP and RAB3IP through its N-terminal region, induces DNA damage and replication stress leading to Mediator-dependent cellular senescence, and promotes formation of intranuclear lamin bodies during S-phase (PMID:12007189, PMID:25363656, PMID:31695025, PMID:34808373). When fused to SS18 via the t(X;18) translocation in synovial sarcoma, the SS18-SSX2 oncoprotein is recruited genome-wide to H3K27me3-marked polycomb chromatin, where it reprograms mesenchymal stem cell differentiation toward neural lineage by coupling SWI/SNF coactivator and PcG corepressor activities, recruits β-catenin to the nucleus, sequesters Slug to derepress E-cadherin, and activates Eph/ephrin signaling to remodel the cytoskeleton (PMID:22594313, PMID:21996728, PMID:16462762, PMID:16849535, PMID:17686994).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 1995 High

    Identification of SSX2 as a KRAB-domain-containing putative transcriptional repressor fused to SYT in the synovial sarcoma t(X;18) translocation established the gene's basic domain architecture and disease relevance.

    Evidence Cloning and sequence analysis of fusion transcripts from synovial sarcoma specimens

    PMID:7539744

    Open questions at the time
    • No direct evidence of transcriptional repression activity at this stage
    • KRAB domain homology does not confirm functional equivalence to canonical KRAB repressors
  2. 2002 High

    Discovery of RAB3IP and SSX2IP as direct N-terminal interaction partners of SSX2, with SSX2 capable of relocalizing RAB3IP to the nucleus, revealed SSX2's capacity to remodel protein subcellular localization.

    Evidence Yeast two-hybrid screen, GST pull-down, immunofluorescence, deletion mapping in transfected cells

    PMID:12007189

    Open questions at the time
    • Physiological relevance of RAB3IP nuclear relocalization unknown
    • Endogenous complex formation not demonstrated
  3. 2006 High

    Multiple studies established that the SS18-SSX2 fusion protein functions as a dual activator-repressor by coupling SWI/SNF coactivation (SS18 moiety) with PcG corepression (SSX2 moiety), deregulating targets including IGF2 and CD44 through epigenetic mechanisms, while also recruiting β-catenin to the nucleus and sequestering Slug to derepress E-cadherin.

    Evidence Conditional expression with microarray profiling, ChIP for histone modifications, bisulfite sequencing, Co-IP, reporter assays, and siRNA knockdown in primary synovial sarcoma cells

    PMID:16462762 PMID:16849535 PMID:17018603

    Open questions at the time
    • How SSX2 moiety directly engages PcG complexes biochemically was not resolved
    • Whether β-catenin and Slug interactions are direct or mediated through SS18 was unclear
  4. 2007 High

    SS18-SSX2 was shown to activate Eph/ephrin signaling to remodel the cytoskeleton and stabilize microtubules, and separately SSX2 expression was found to be silenced by DNA methylation in normal tissues.

    Evidence EphB2 signaling blockade rescue experiments with immunofluorescence and nocodazole resistance; RT-PCR after 5-aza-2'-deoxycytidine treatment

    PMID:17686994 PMID:17929270

    Open questions at the time
    • Direct transcriptional target linking SS18-SSX2 to EphB2 upregulation not identified
    • Methylation-based silencing not mapped to specific CpG islands
  5. 2009 Medium

    The SSX2 portion of SS18-SSX2 was shown to destabilize the PcG subunit Bmi1 and impair H2A ubiquitination, providing a mechanism for PcG target gene reactivation, while a C-terminal NLS was identified as necessary for nuclear targeting.

    Evidence Co-IP, H2A ubiquitination western blotting, RT-PCR for PcG target reactivation; NLS deletion mutant analysis in yeast

    PMID:19337376 PMID:19826807

    Open questions at the time
    • Bmi1 destabilization mechanism (proteasomal vs. transcriptional) not defined
    • NLS function validated only in yeast, not mammalian cells
  6. 2011 High

    Genome-wide ChIP analysis revealed that SS18-SSX2 directly occupies and activates neural-specific genes while suppressing myogenic programs in mesenchymal stem cells, with FGFR2 identified as a critical direct target whose knockdown abrogates sarcoma cell growth.

    Evidence Genome-wide ChIP, retroviral transduction of mesenchymal stem cells, FGFR2 siRNA knockdown with differentiation and growth assays

    PMID:21996728

    Open questions at the time
    • Whether FGFR2 activation is sufficient for lineage reprogramming not tested
    • Cell-of-origin for synovial sarcoma in vivo not established by this study
  7. 2012 High

    ChIP-seq demonstrated that SS18-SSX2 is recruited genome-wide to H3K27me3-marked polycomb chromatin, with gene activation correlating to proximal occupancy and repression to distal occupancy or ATF2/TLE1 corepressor recruitment at specific promoters (MCL1, BCL2A1).

    Evidence Genome-wide ChIP-seq with integrated expression profiling; ChIP and reporter assays at MCL1/BCL2A1 promoters with TLE1 Co-IP

    PMID:22594313 PMID:22797074

    Open questions at the time
    • Whether SS18-SSX2 directly contacts H3K27me3 or is recruited via adaptor proteins remains unresolved
    • Structural basis of ATF2/TLE1 interaction not determined
  8. 2014 High

    Wild-type SSX2 was established as a chromatin-associated, sequence-nonspecific DNA-binding protein that antagonizes PcG body formation and H3K27me3 levels through an indirect mechanism, and whose ectopic expression induces DNA damage, replication stress, and p53-dependent senescence.

    Evidence EMSA/DNA pulldown, ChIP for H3K27me3, immunofluorescence for PcG bodies; flow cytometry, γH2AX immunofluorescence, β-galactosidase senescence assay with knockdown controls

    PMID:25249625 PMID:25363656

    Open questions at the time
    • Molecular mechanism by which SSX2 disrupts PcG bodies without altering complex composition is unknown
    • Whether DNA damage is a direct consequence of chromatin binding or an indirect effect not resolved
  9. 2019 Medium

    A functional genetic screen identified the Mediator complex (MED1, MED4, MED14) as specifically required for SSX2-induced senescence, distinguishing SSX2's senescence pathway from oncogene- or drug-induced senescence.

    Evidence RNAi library screen with siRNA validation, specificity controls against B-Raf and Epirubicin senescence, RNA-seq

    PMID:31695025

    Open questions at the time
    • Whether SSX2 directly contacts Mediator subunits or acts through transcriptional intermediaries unknown
    • How Mediator engagement relates to PcG antagonism not clarified
  10. 2021 Medium

    SSX2 was found to induce novel intranuclear lamin A/B bodies in an S-phase-dependent manner, independent of its known PcG and Mediator interactions, revealing a previously unrecognized effect on nuclear architecture.

    Evidence Immunofluorescence in breast epithelial cell lines, cell cycle synchronization, Co-IP to exclude PcG/Mediator involvement

    PMID:34808373

    Open questions at the time
    • Functional consequence of lamin body formation not determined
    • Whether lamin body formation is linked to DNA damage or replication stress phenotypes not tested
    • Biochemical reconstitution of SSX2-lamin interaction not performed

Open questions

Synthesis pass · forward-looking unresolved questions
  • The molecular mechanism by which SSX2 disrupts PcG body formation without altering complex composition, the structural basis of its sequence-nonspecific DNA binding, and how its chromatin remodeling, Mediator-dependent senescence, and lamin body formation activities are integrated remain unresolved.
  • No structural model of SSX2 bound to DNA or chromatin
  • No reconstituted system defining minimal domains for PcG antagonism
  • Relationship between lamin body formation, replication stress, and senescence unexplored

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 3 GO:0003677 DNA binding 1
Localization
GO:0005634 nucleus 4 GO:0005694 chromosome 1
Pathway
R-HSA-4839726 Chromatin organization 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1640170 Cell Cycle 2
Partners
ATF2BMI1CTNNB1RAB3IPSNAI2SSX2IPTLE1

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1995 SSX2 protein contains an N-terminal domain with homology to the Kruppel-associated box (KRAB), a transcriptional repressor domain, identifying SSX2 as encoding a putative transcriptional repressor. The SYT-SSX2 fusion results from the t(X;18)(p11.2;q11.2) chromosomal translocation in synovial sarcoma. Sequence analysis of cloned fusion transcripts from synovial sarcoma specimens The EMBO journal High 7539744
2002 SSX2 interacts directly with two novel proteins: RAB3IP (human homologue of a Ras-like GTPase interactor) and SSX2IP (a novel nuclear protein). Both interactions occur via the N-terminal moiety of SSX2. Coexpression of SSX2 with RAB3IP relocates RAB3IP from the cytoplasm to the nucleus, and SSX2IP colocalizes with SSX2 in the nucleus. Yeast two-hybrid screen, GST pull-down assays (in vitro direct interaction), immunofluorescence of transfected cells, deletion mutant analysis Genes, chromosomes & cancer High 12007189
2006 The SYT-SSX2 fusion protein recruits beta-catenin to the nucleus and forms a transcriptionally active nuclear complex with it, independent of canonical Wnt signaling. Depletion of SYT-SSX2 in primary synovial sarcoma cells results in loss of nuclear beta-catenin and decreased beta-catenin signaling activity. Co-immunoprecipitation, subcellular fractionation, reporter assays, siRNA knockdown in primary synovial sarcoma cells Oncogene High 16462762
2006 SYT-SSX1 interacts preferentially with the transcriptional repressor Snail, while SYT-SSX2 interacts preferentially with Slug. Both fusion proteins prevent their respective repressors from binding the proximal E-cadherin promoter, thereby derepressing E-cadherin transcription. Coimmunoprecipitation, chromatin immunoprecipitation (ChIP), luciferase reporter assays Cancer research High 16849535
2006 The SS18-SSX2 fusion protein functions as a transcriptional 'activator-repressor' that deregulates downstream target genes (including IGF2 and CD44) through epigenetic mechanisms, affecting histone modifications at CD44 and IGF2 promoters and DNA methylation levels at the IGF2 imprinting control region. SS18 moiety is associated with the SWI/SNF complex (coactivator) while SSX moiety is associated with the polycomb complex (corepressor), and both activities are retained in the fusion. Conditional expression system, cDNA microarray profiling, chromatin immunoprecipitation for histone modifications, bisulfite sequencing for DNA methylation Cancer research High 17018603
2007 SYT-SSX2 remodels the cytoskeleton by activating the Eph/ephrin signaling pathway, inducing cell elongation, neurite-like extensions, and cell repulsion. SYT-SSX2 also independently stabilizes the microtubule network through accumulation of detyrosinated Glu tubulin. Blockade of EphB2 signaling reverses the aberrant cytoskeletal phenotype. Retroviral transduction, immunofluorescence, EphB2 signaling blockade rescue experiments, western blotting for Glu tubulin, nocodazole resistance assay, immunohistochemistry of synovial sarcoma tissues Molecular biology of the cell High 17686994
2009 SYT-SSX2 interacts with the polycomb repressive complex and causes destabilization of the polycomb subunit Bmi1, resulting in impaired polycomb-associated histone H2A ubiquitination and reactivation of polycomb target genes. Co-immunoprecipitation, western blotting for H2A ubiquitination, RT-PCR for polycomb target gene reactivation PloS one Medium 19337376
2011 SYT-SSX2 reprograms myogenic progenitors and human bone marrow-derived mesenchymal stem cells by directly occupying and activating neural-specific genes while suppressing normal myogenic and adipogenic differentiation programs. SYT-SSX2 directly targets and upregulates FGFR2, and FGFR2 knockdown abrogates growth and attenuates the neural phenotype of both mesenchymal stem cells and synovial sarcoma cells. Retroviral transduction, genome-wide ChIP analysis, siRNA knockdown of FGFR2, differentiation assays, gene expression profiling Oncogene High 21996728
2012 SS18-SSX2 increases BCL2 expression but represses other anti-apoptotic genes MCL1 and BCL2A1 by directly suppressing their expression via binding through ATF2 to the CRE in the promoters of these genes and recruiting TLE1/Groucho corepressor. ChIP, promoter reporter assays, co-immunoprecipitation, siRNA knockdown, in vitro and in vivo pharmacological studies with ABT-263 Oncogene High 22797074
2012 SYT-SSX2 is recruited genome-wide predominantly to polycomb-modified chromatin sites enriched with H3K27me3. Activated genes show SYT-SSX2/H3K27me3 sites within their body or near TSS, while downregulated genes are characterized by SYT-SSX2/H3K27me3 at long-range positions or by activation marks within the gene body. Genome-wide ChIP-seq, expression profiling, hierarchical clustering of epigenetic marks BMC genomics High 22594313
2014 SSX2 is a chromatin-associated protein that binds double-stranded DNA in a sequence non-specific manner and antagonizes BMI1 and EZH2 polycomb group body formation, derepressing PcG target genes and negatively regulating H3K27me3 levels in melanoma cells. SSX2 antagonizes PcG function through an indirect mechanism without directly affecting overall PcG complex composition. Chromatin fractionation, DNA binding assays (EMSA/pulldown), immunofluorescence for PcG body formation, ChIP for H3K27me3, gene expression analysis after SSX2 knockdown/overexpression Nucleic acids research High 25249625
2014 Ectopic SSX2 expression induces DNA damage, replication stress, genomic instability (increased DNA content, enlarged nuclei, DNA double-strand breaks), p53-mediated G1 cell cycle arrest, and a late apoptotic response in melanoma and breast cancer cells. Knockdown of SSX2 in melanoma cell lines reduces tumor cell growth, demonstrating SSX2 supports melanoma cell proliferation. Stable transfection/overexpression, flow cytometry for DNA content, immunofluorescence for γH2AX (DNA damage marker), β-galactosidase senescence assay, siRNA knockdown with proliferation assays Molecular oncology Medium 25363656
2016 SSX2 knockdown in prostate cancer cells results in epithelial morphology, increased cell proliferation, increased expression of genes involved in focal adhesion, decreased anchorage-independent growth, increased invasion, and increased tumorigenicity in vivo, indicating SSX2 regulates focal adhesion-related processes rather than driving EMT. siRNA knockdown, overexpression, morphological analysis, gene expression profiling, invasion assays, in vivo tumorigenicity assay Oncotarget Medium 27276714
2019 The Mediator complex is essential for SSX2-induced senescence; knockdown of MED1, MED4, and MED14 subunits perturbs SSX2-induced senescence development. This effect is specific to SSX2-induced senescence, as MED1 knockdown did not prevent B-Raf- or Epirubicin-induced senescence. Functional genetic screen (RNAi library), siRNA validation knockdown experiments, β-galactosidase senescence assay, immunostaining of melanoma tumors vs. benign nevi, RNA-seq analysis Cell death & disease Medium 31695025
2021 SSX2 induces the formation of a novel type of intranuclear lamin bodies containing both A and B type lamins but no other nuclear lamina components. This effect is dependent on S-phase progression and is independent of known SSX2 interactions with polycomb proteins and the Mediator complex. Immunofluorescence in multiple breast epithelial cell line models, cell cycle synchronization experiments, co-immunoprecipitation to test polycomb/Mediator involvement The international journal of biochemistry & cell biology Medium 34808373
2007 SSX2 expression in prostate cancer cell lines can be induced by treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine, indicating that SSX2 expression is regulated by DNA methylation. Normal prostate epithelial cells do not show SSX2 induction under the same treatment. RT-PCR after 5-aza-2'-deoxycytidine treatment in cancer cell lines vs. normal cell line The Prostate Medium 17929270
2009 SSX2 contains a C-terminal nuclear localization signal (NLS) that is required for its nuclear targeting. When expressed in Pichia pastoris, SSX2 containing the NLS accumulates in the endoplasmic reticulum in misfolded form rather than translocating to the nucleus, whereas deletion of the NLS allows correct folding and secretion. Indirect immunofluorescence of SSX2 and NLS-deletion mutant expressed in yeast, secretion assays, protein folding analysis Applied microbiology and biotechnology Low 19826807
2012 SSX2 overexpression in MCF-7 breast cancer cells suppresses ERα and E-cadherin expression, promotes cell invasion in vitro and in vivo, and differentially regulates a set of proteins identified by comparative proteomics. Stable transfection, MTT assay, flow cytometry, transwell invasion assay, in vivo tumorigenicity assay, 2D-gel comparative proteomics International journal of oncology Low 22344619
2018 RAB3IP interacts with SSX2 and co-expression of RAB3IP and SSX2 is correlated in gastric cancer; RAB3IP promotes an invasive phenotype and is associated with epithelial-mesenchymal transition markers. Co-immunoprecipitation, western blotting, invasion assays in gastric cancer cell lines, expression correlation analysis Biochemical and biophysical research communications Low 30005870

Source papers

Stage 0 corpus · 61 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1995 Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. The EMBO journal 411 7539744
1996 The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer research 193 8840996
1995 Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript. The American journal of pathology 137 7495284
2006 SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. Cancer research 94 16849535
2006 The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer research 81 17018603
2015 PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer immunology research 71 26041735
2014 Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 59 24457462
2011 Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2. Oncogene 57 21996728
2006 The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex. Oncogene 57 16462762
2002 The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase interactor, RAB3IP, and a novel nuclear protein, SSX2IP. Genes, chromosomes & cancer 54 12007189
2007 Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. The Prostate 42 17929270
2001 Primary synovial sarcoma of the kidney: Report of a case confirmed by molecular detection of the SYT-SSX2 fusion transcripts. Pathology international 39 11422798
2014 Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability. Molecular oncology 33 25363656
2012 SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. Oncogene 33 22797074
2011 Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. Journal of immunotherapy (Hagerstown, Md. : 1997) 32 21904219
2002 Co-existence of SYT-SSX1 and SYT-SSX2 fusions in synovial sarcomas. Oncogene 32 12037676
2012 Genome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2. BMC genomics 31 22594313
2015 β-catenin stabilization enhances SS18-SSX2-driven synovial sarcomagenesis and blocks the mesenchymal to epithelial transition. Oncotarget 30 26259251
2009 The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1. PloS one 26 19337376
2007 The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway. Molecular biology of the cell 24 17686994
2002 Cryptic t(X;18), ins(6;18), and SYT-SSX2 gene fusion in a case of intraneural monophasic synovial sarcoma. Cancer genetics and cytogenetics 24 12505262
2001 Calcifying/ossifying synovial sarcoma shows t(X;18) with SSX2 involvement and mitochondrial calcifications. Histopathology 24 11207827
2007 Primary monophasic synovial sarcoma of the duodenum with SYT/SSX2 type of translocation. Human pathology 21 17509396
2014 Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer. PloS one 19 24681846
2004 Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. International journal of cancer 19 15382048
2014 SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression. Nucleic acids research 18 25249625
2014 SSX2-4 expression in early-stage non-small cell lung cancer. Tissue antigens 17 24645645
2014 Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation. Cancer immunology, immunotherapy : CII 17 25078248
2021 Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia. Molecular therapy. Methods & clinical development 16 34729377
2004 Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells. Journal of immunology (Baltimore, Md. : 1950) 16 15153546
2003 Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2. Cancer immunity 16 14677925
2014 DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses. Vaccine 15 24492013
2005 Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2. Clinical immunology (Orlando, Fla.) 15 15596411
2002 Real-time polymerase chain reaction as an aid for the detection of SYT-SSX1 and SYT-SSX2 transcripts in fresh and archival pediatric synovial sarcoma specimens: report of 25 cases from St. Jude Children's Research Hospital. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 14 12469233
1996 Affinities and intrinsic activities of dopamine receptor agonists for the hD21 and hD4.4 receptors. European journal of pharmacology 14 8773470
2012 Cancer/testis antigen SSX2 enhances invasiveness in MCF-7 cells by repressing ERα signaling. International journal of oncology 13 22344619
2008 Cryptic chromosome rearrangement resulting in SYT-SSX2 fusion gene in a monophasic synovial sarcoma. Cancer genetics and cytogenetics 13 18992642
2011 A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses. Cancer immunology, immunotherapy : CII 12 21630107
2011 Synovial sarcoma of the tongue confirmed by molecular detection of the SYT-SSX2 fusion gene transcript. International journal of surgical pathology 12 22007079
2021 Undifferentiated sarcoma of bone with a round to epithelioid cell phenotype harboring a novel EWSR1-SSX2 fusion identified by RNA-based next-generation sequencing. Genes, chromosomes & cancer 11 34538011
2018 Rab3IP interacts with SSX2 and enhances the invasiveness of gastric cancer cells. Biochemical and biophysical research communications 10 30005870
2018 Antitumor effect of recombinant Mycobacterium smegmatis expressing MAGEA3 and SSX2 fusion proteins. Experimental and therapeutic medicine 10 30186454
2016 SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. Oncotarget 8 27276714
2007 Expression and purification of the cancer antigen SSX2: a potential cancer vaccine. Protein expression and purification 8 17931884
2006 A variant of the SYT-SSX2 fusion gene in a case of synovial sarcoma. Cancer genetics and cytogenetics 8 16682293
2002 A rare synovial sarcoma of the kidney exhibiting translocation (X;18) and SYT-SSX2 fusion gene. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed 8 12201571
2003 SYT-SSX2 variant of primary pulmonary synovial sarcoma with focal expression of CD117 (c-Kit) protein and a poor clinical outcome. Archives of pathology & laboratory medicine 7 12683902
2002 Expression of SSX-2 and SSX-4 genes in neuroblastoma. The International journal of biological markers 6 12521124
2010 Primary pulmonary biphasic synovial sarcoma confirmed by molecular detection of a SYT-SSX2 fusion gene: report of 1 case. The Korean journal of internal medicine 5 20830232
2009 Improved secretion of the cancer-testis antigen SSX2 in Pichia pastoris by deletion of its nuclear localization signal. Applied microbiology and biotechnology 5 19826807
2008 A t(X; 18) SYT-SSX2 positive synovial sarcoma in the pelvis of a young adult male: a rare case report with review of literature. Indian journal of cancer 5 18626152
2004 Are there geographical differences in the frequency of SYT-SSX1 and SYT-SSX2 chimeric transcripts in synovial sarcoma? Cancer detection and prevention 5 15350633
2020 Primary monophasic synovial sarcoma of the cervical esophagus confirmed by detection of the SS18-SSX2 fusion transcripts: case report and literature review. Surgical case reports 4 32691176
2019 A functional genetic screen identifies the Mediator complex as essential for SSX2-induced senescence. Cell death & disease 4 31695025
2012 Primary Monophasic Synovial Sarcoma Arising in the Mesentery: Case Report of an Extremely Rare Mesenteric Sarcoma Confirmed by Molecular Detection of a SYT-SSX2 Fusion Transcript. Korean journal of pathology 4 23109999
2018 Primary Synovial Sarcoma arising from gingivo-buccal sulcus harbouring SS18-SSX2 positive fusion transcript: The 1st reported case in English literature. Journal of stomatology, oral and maxillofacial surgery 3 29325767
2011 [Analysis of SYT/SSX1 and SYT/SSX2 fusion genes from synovial sarcoma]. Molekuliarnaia biologiia 2 22393780
2021 SSX2 promotes the formation of a novel type of intranuclear lamin bodies. The international journal of biochemistry & cell biology 1 34808373
2026 MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay. Blood 0 41662627
2006 Expression of SSX2 tumor antigen in baculovirus expression system and its application for screening of blood serum of melanoma patients. Experimental oncology 0 16837900
2005 [Expression of SSX2 gene in human urologic neoplasms]. Zhonghua wai ke za zhi [Chinese journal of surgery] 0 15854347